MIR8064: A Potential Drug Target and Biomarker for Melanoma (G102465866)

MIR8064: A Potential Drug Target and Biomarker for Melanoma

Melanoma is a type of skin cancer that is characterized by the rapid growth and progression of cancerous cells in the melanin-producing skin cells. It is a leading cause of skin cancer worldwide and has a high mortality rate due to its aggressive and deadly nature. Despite advances in treatment, the survival rate for melanoma remains poor, with a five-year survival rate of only around 40%.

Recent studies have identified several potential drug targets and biomarkers for melanoma. One of these targets is MIR8064, a non-coding RNA molecule that has been identified in several studies as a potential drug target for melanoma. MIR8064 is a highly conserved gene that is expressed in many tissues and has been implicated in several cellular processes, including cell growth, apoptosis, and inflammation.

Several studies have demonstrated that MIR8064 is involved in the development and progression of melanoma. For example, a study published in the journal Oncogene found that high levels of MIR8064 were associated with poor prognosis in patients with melanoma. The authors suggested that targeting MIR8064 may be a promising strategy for the development of new treatments for melanoma.

Another study published in the journal PLoS Medicine found that MIR8064 was overexpressed in melanoma tissue and was associated with poor clinical outcomes in patients with melanoma. The authors suggested that targeting MIR8064 may be a potential biomarker for melanoma and that further research is needed to determine its utility as a drug target.

Furthermore, a study published in the journal Cancer Research found that MIR8064 was expressed in human melanoma and was associated with the development of metastasis. The authors suggested that targeting MIR8064 may be a potential strategy for the development of new treatments for melanoma.

In addition to its potential as a drug target, MIR8064 has also been identified as a potential biomarker for melanoma. Several studies have demonstrated that MIR8064 is expressed in melanoma tissue and is associated with poor clinical outcomes in patients with melanoma. For example, a study published in the journal Skin Research and Technology found that MIR8064 was overexpressed in melanoma tissue and was associated with poor skin reaction to sun exposure in patients with melanoma.

The high level of MIR8064 expression in melanoma tissue may have implications for the development of new treatments for this disease. Targeting MIR8064 with small molecules or antibodies has been shown to be effective in animal models of melanoma. For example, a study published in the journal Nature Medicine found that a small molecule inhibitor of MIR8064 was effective in inhibiting the growth of melanoma cells in a culture dish.

In conclusion, MIR8064 is a potential drug target and biomarker for melanoma. Its high level of expression in melanoma tissue and its involvement in several cellular processes make it an attractive target for drug development. Further research is needed to determine the effectiveness of targeting MIR8064 as a drug or biomarker for melanoma.

Protein Name: MicroRNA 8064

The "MIR8064 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR8064 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex